An open-label, prospective, randomized study of the effect of PEGASYS [peginterferon alfa-2a] plus ribavirin, with or without amantadine, on sustained virological response in patients with chronic hepatitis C viral infection who either did not respond or relapsed after prior treatment with interferon plus ribavirin
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2010
At a glance
- Drugs Amantadine; Peginterferon alfa-2a; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
- 08 Jun 2006 New trial record.